Avery Dennison Declares Quarterly Dividend
Get Alerts AVY Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.2%
Revenue Growth %: +1.8%
Join SI Premium – FREE
MENTOR, Ohio--(BUSINESS WIRE)-- Avery Dennison Corporation (NYSE: AVY), a leading global materials science and digital identification solutions company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.94 per share. The dividend is payable on September 17, 2025 to shareholders of record on September 3, 2025.
About Avery Dennison
Avery Dennison Corporation (NYSE: AVY) is a global materials science and digital identification solutions company. We are Making Possible™ products and solutions that help advance the industries we serve, providing branding and information solutions that optimize labor and supply chain efficiency, reduce waste, advance sustainability, circularity and transparency, and better connect brands and consumers. We design and develop labeling and functional materials, radio frequency identification (RFID) inlays and tags, software applications that connect the physical and digital, and offerings that enhance branded packaging and carry or display information that improves the customer experience. Serving industries worldwide — including home and personal care, apparel, general retail, e-commerce, logistics, food and grocery, pharmaceuticals and automotive — we employ approximately 35,000 employees in more than 50 countries. Our reported sales in 2024 were $8.8 billion. Learn more at www.averydennison.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724856994/en/
William Gilchrist
Vice President, Investor Relations
[email protected]
Kristin Robinson
Vice President, Global Communications
[email protected]
Source: Avery Dennison Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
- Reliable Roofing Expands Crews to Get Front Range Roofs Done Before Snowfall
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share